# Cagrilintide and Semaglutide: Two Hormone Families, Two Receptor Systems > Why these molecules are complementary rather than rival tools, how to design a comparison, and the handling differences that catch laboratories out. Web page: https://peptidemedixeu.com/en/learn/cagrilintide-vs-semaglutide/ · Peptide Medix EU · 5 min read · Updated: 2026-07-02 Treating [cagrilintide](https://peptidemedixeu.com/en/learn/what-is-cagrilintide/) and semaglutide as rival versions of one idea misreads both. Different hormones gave rise to them and different receptors receive them: the first is a long-acting amylin analogue signalling at calcitonin and amylin receptor complexes, the second an acylated GLP-1 analogue signalling at the GLP-1 receptor. For that reason the literature generally casts them as complementary instruments rather than rivals, and the combination investigated as CagriSema exists exactly because the pathways are distinct. Setting cagrilintide against [semaglutide](https://peptidemedixeu.com/en/learn/what-is-semaglutide/) is therefore really a question of which satiation signalling route your model is equipped to read. Each arrives as sealed lyophilized powder with its own HPLC certificate, cagrilintide at 5 and 10 mg and semaglutide at 5, 10, 20, 30 and 50 mg, both catalogued among GLP-1 and incretin peptides. Neither counts as a medicine; both are research chemicals restricted to laboratory use. ## Separate hormones, not two takes on one [Amylin itself](https://peptidemedixeu.com/en/glossary/amylin/) is a 37-residue peptide released alongside insulin by pancreatic beta cells. Its signalling runs through complexes that form when the calcitonin receptor pairs with receptor-activity-modifying proteins, giving the AMY1, AMY2 and AMY3 phenotypes, and published work links it to satiation and to slower gastric emptying. Human amylin is famously difficult to handle because it assembles into amyloid fibrils in solution, which makes native material a poor bench reagent. Cagrilintide tackles both issues together, using sequence substitutions that suppress fibril formation plus a lipid side chain that supplies reversible albumin binding and a long working window. The full structural account is in what is cagrilintide. Semaglutide arrives from the other end of the gut-islet axis. Built on GLP-1(7-37), the [incretin secreted](https://peptidemedixeu.com/en/glossary/incretin/) after nutrients arrive, it is protected from dipeptidyl peptidase-4 by an Aib substitution and acylated with a C18 diacid. It targets one receptor only, the GLP-1 receptor, and serves as the standard reference agonist for it in comparative panels. ## Why the two pathways are combined These molecules appear together in the literature because their central targets overlap anatomically while remaining separate pharmacologically. Amylin receptor signalling has been mapped prominently to the area postrema and neighbouring hindbrain nuclei, and GLP-1 receptor signalling has been described in overlapping hindbrain regions as well as hypothalamic circuits. Different receptors feeding converging circuits make an amylin analogue plus an incretin agonist a test of whether two independent satiation inputs add up, multiply or duplicate each other. That is the stated premise of the pairing covered in our [CagriSema](https://peptidemedixeu.com/en/products/semaglutide-cagrilintide/) and amylin analogs briefing, and the reason a fixed combination such as semaglutide with cagrilintide exists as a research article at all. ### Setting up an amylin-versus-incretin comparison 1. Verify receptor expression first: an AMY phenotype needs the calcitonin receptor together with the appropriate RAMP, so a line carrying the calcitonin receptor alone is not an amylin receptor system. 2. Work in molar units, since at 4409.07 and 4113.58 g/mol the two differ by roughly 7%, enough to skew any mass-matched comparison. 3. Test each molecule on its own before testing them together, because a combination arm lacking both mono-arms cannot separate additivity from redundancy. 4. If gastric emptying is the endpoint, remember both pathways affect it, so the combination arm requires a longer observation period than either alone. 5. Where a shorter-acting amylin comparator is needed, pramlintide is the customary reference. ## What has been studied Publications on cagrilintide cluster around the calcitonin receptor with its RAMP partners, satiation pathways in the area postrema and hypothalamus, gastric emptying endpoints in animals, and combination studies with incretin agonists. Because native amylin fibrillates so readily, much of the analogue literature is chemistry rather than pharmacology: whether anti-fibrillation substitutions leave receptor activity intact, and how the lipid side chain alters distribution. The semaglutide record is larger and differently shaped, covering GLP-1 receptor binding and cyclic-AMP kinetics in transfected lines, beta-arrestin recruitment and internalisation, insulin secretion from isolated islets and beta-cell lines, and rodent studies of food intake and body composition. Human trial data exist for approved prescription products containing semaglutide and for investigational products containing cagrilintide, but those studies describe regulated articles administered under medical supervision rather than research-grade peptide. Both compounds are surveyed against their alternatives in the weight-loss peptide research overview. ## Matching compound to question - Amylin receptor pharmacology, RAMP-dependent signalling or calcitonin receptor work calls for cagrilintide, since semaglutide is inactive at those receptors. - GLP-1 receptor pharmacology and incretin potency panels call for semaglutide, since cagrilintide does nothing at that receptor. - Gastric emptying and satiation circuitry call for both, run as separate arms, because the two pathways affect overlapping endpoints through different receptors. - Testing whether independent satiation signals add up calls for both plus a combination arm, preferably in a fixed ratio so the comparison can be repeated. - Amyloid and aggregation chemistry calls for cagrilintide as the engineered counterpoint to native amylin's fibrillation. - Adding a second incretin receptor rather than a second hormone family is covered in semaglutide vs tirzepatide. ## Differences in handling and storage Both are lyophilized powders kept sealed at −20 °C away from light and moisture, then held at 2-8 °C once reconstituted, protected from light and used inside the study window. The general principles appear in how to store peptides. Their chemistry differs, though. Cagrilintide carries an intramolecular disulfide, so any reducing agent in the buffer will compromise it, and it belongs to a peptide family with well-documented aggregation behaviour: make solutions fresh, look at concentrated stocks before use, and never vortex, since the shear and air interface that creates are exactly what nucleates aggregation. Dilute buffers rather than plain water are common wherever assay pH matters. Semaglutide presents a different problem: its C18 acyl chain leaves it [sufficiently lipophilic](https://peptidemedixeu.com/en/glossary/lipophilic/) to stick to ordinary plastics at low concentrations, which low-binding tubes and plates usually solve. Neither molecule copes well with repeated freeze-thaw, and [aliquoting](https://peptidemedixeu.com/en/learn/aliquoting-peptides/) after reconstitution is the standard remedy for both. ### A worked concentration using the 5 mg vials Both are stocked in a 5 mg format, which makes the arithmetic directly comparable. Reconstitute 5 mg in 2 mL of bacteriostatic water and you have 2.5 mg/mL. In molar terms, 2.5 mg/mL divided by 4409.07 g/mol gives roughly 567 micromolar for cagrilintide, whereas the same 2.5 mg/mL of semaglutide at 4113.58 g/mol gives roughly 608 micromolar. A 7% offset is invisible on a label yet plain in a fitted curve, so write down both the mass concentration prepared and the [molar concentration](https://peptidemedixeu.com/en/glossary/molarity/) used. Working stocks for cell assays are normally diluted from this into assay buffer immediately before use rather than stored dilute, because dilute peptide solutions lose material to surfaces faster than concentrated ones do. ## Checking purity and identity Ask for the lot-matched certificate for each and read three items: HPLC purity with the trace visible, a mass spectrometry result matching the expected weight (4409.07 g/mol for cagrilintide, 4113.58 g/mol for semaglutide), and a lot number matching the vial. Cagrilintide needs one additional check the incretin analogues do not: confirm the material is the oxidised, disulfide-closed form rather than the reduced linear species, since only about 2 Da separate them while their receptor behaviour differs sharply. Counter-ion content and residual water mean the labelled mass overstates net peptide in both cases, so anchor comparative work to a measured concentration. ## Regulatory framing Authorised prescription products contain semaglutide as their active substance, while cagrilintide has appeared within investigational clinical programmes. Any human evidence therefore attaches to those regulated articles and the supervised settings that produced it, never to reagent-grade material. ## Frequently asked questions ### How do cagrilintide and semaglutide differ? They belong to different hormone families. Cagrilintide is a long-acting version of amylin, the beta-cell hormone signalling through calcitonin receptor-RAMP complexes (AMY1-AMY3), while semaglutide is an acylated version of the intestinal incretin GLP-1 acting at the GLP-1 receptor. Neither has activity at the other's receptor. ### Why study them together instead of head to head? Their receptors are separate while the hindbrain and hypothalamic circuits they influence overlap. Putting them together tests whether two independent satiation inputs prove additive, synergistic or redundant, which is the stated basis for amylin-plus-incretin designs and for fixed-combination research articles. ### Will a calcitonin receptor line work as an amylin receptor system? Not by itself. Amylin receptor phenotypes only appear when the calcitonin receptor partners with receptor-activity-modifying proteins. A line expressing the calcitonin receptor without the relevant RAMP reports calcitonin receptor pharmacology rather than AMY1-AMY3 pharmacology, and cagrilintide data from it should be described that way. ### Does cagrilintide require different handling? Yes, on two counts. It contains an intramolecular disulfide, so reducing agents in a buffer will damage it, and its peptide family is known for aggregation, so mix gently, avoid vortexing and inspect concentrated stocks. Semaglutide's difficulty is lipophilic adsorption onto plastics, which low-binding labware addresses. ### Can they be swapped at matched milligram amounts? No. Quite apart from targeting different receptors, they differ by about 7% in molecular weight, 4409.07 against 4113.58 g/mol, so equal masses are not equal molar concentrations. Build every comparative series in molar units. ### What additional check belongs on a cagrilintide certificate? Confirmation that the material is the oxidised, disulfide-closed species rather than the reduced linear form. Only around 2 Da separate them, yet their receptor behaviour differs considerably, so read the mass spectrometry result carefully alongside the HPLC trace and the lot number on the vial. ### Do human clinical results apply to research-grade material? They do not. Semaglutide is the active substance of approved prescription medicines and cagrilintide has appeared in investigational programmes, but that evidence describes regulated articles given under medical supervision. The research-grade peptide supplied here is a separate article for laboratory use only. ## Related products - [Cagrilintide](https://peptidemedixeu.com/en/products/cagrilintide/): from €97 - [Semaglutide](https://peptidemedixeu.com/en/products/semaglutide/): from €38 --- For laboratory research use only. This page is provided for scientific and educational information. Materials referenced here are sold strictly for in-vitro laboratory research by qualified professionals — not for human or veterinary use, and nothing on this page is medical advice.